Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 176.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 459,369 shares of the biopharmaceutical company's stock after acquiring an additional 292,926 shares during the period. Federated Hermes Inc. owned approximately 0.35% of Halozyme Therapeutics worth $16,978,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vontobel Holding Ltd. purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at about $249,000. Exchange Traded Concepts LLC raised its stake in shares of Halozyme Therapeutics by 16.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 14,129 shares of the biopharmaceutical company's stock valued at $540,000 after buying an additional 1,974 shares during the last quarter. Handelsbanken Fonder AB raised its stake in shares of Halozyme Therapeutics by 8.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 23,869 shares of the biopharmaceutical company's stock valued at $912,000 after buying an additional 1,800 shares during the last quarter. Linden Thomas Advisory Services LLC raised its stake in shares of Halozyme Therapeutics by 13.7% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 42,450 shares of the biopharmaceutical company's stock valued at $1,622,000 after buying an additional 5,126 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in shares of Halozyme Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company's stock valued at $619,000 after buying an additional 347 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on HALO shares. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, April 17th. StockNews.com upgraded Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, February 23rd. TheStreet cut Halozyme Therapeutics from a "b-" rating to a "c+" rating in a research report on Monday, January 22nd. Morgan Stanley dropped their target price on Halozyme Therapeutics from $61.00 to $59.00 and set an "overweight" rating on the stock in a research report on Tuesday, December 26th. Finally, The Goldman Sachs Group dropped their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating on the stock in a research report on Thursday, January 18th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of "Moderate Buy" and an average target price of $53.29.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the sale, the senior vice president now directly owns 156,558 shares in the company, valued at approximately $6,519,075.12. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 30,000 shares of company stock worth $1,196,800. Insiders own 2.70% of the company's stock.

Halozyme Therapeutics Price Performance

HALO stock traded up $0.26 during trading on Tuesday, hitting $38.97. The stock had a trading volume of 557,947 shares, compared to its average volume of 1,252,820. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. Halozyme Therapeutics, Inc. has a twelve month low of $29.85 and a twelve month high of $45.00. The stock has a market capitalization of $4.95 billion, a P/E ratio of 18.48, a PEG ratio of 0.45 and a beta of 1.25. The company's 50-day moving average price is $39.62 and its two-hundred day moving average price is $37.78.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.